1338226-11-1Relevant articles and documents
Discovery of MK-1439, an orally bioavailable non-nucleoside reverse transcriptase inhibitor potent against a wide range of resistant mutant HIV viruses
C?té, Bernard,Burch, Jason D.,Asante-Appiah, Ernest,Bayly, Chris,Bédard, Leanne,Blouin, Marc,Campeau, Louis-Charles,Cauchon, Elizabeth,Chan, Manuel,Chefson, Amandine,Coulombe, Nathalie,Cromlish, Wanda,Debnath, Smita,Deschênes, Denis,Dupont-Gaudet, Kristina,Falgueyret, Jean-Pierre,Forget, Robert,Gagné, Sébastien,Gauvreau, Danny,Girardin, Melina,Guiral, Sébastien,Langlois, Eric,Li, Chun Sing,Nguyen, Natalie,Papp, Rob,Plamondon, Serge,Roy, Amélie,Roy, Stéphanie,Seliniotakis, Ria,St-Onge, Miguel,Ouellet, Stéphane,Tawa, Paul,Truchon, Jean-Fran?ois,Vacca, Joe,Wrona, Marc,Yan, Youwei,Ducharme, Yves
, p. 917 - 922 (2014/02/14)
The optimization of a novel series of non-nucleoside reverse transcriptase inhibitors (NNRTI) led to the identification of pyridone 36. In cell cultures, this new NNRTI shows a superior potency profile against a range of wild type and clinically relevant,
